Literature DB >> 31421952

High Flow Nasal Cannula Oxygen vs. Conventional Oxygen Therapy and Noninvasive Ventilation in Emergency Department Patients: A Systematic Review and Meta-Analysis.

Valentina Tinelli1, Luca Cabrini2, Evgeny Fominskiy2, Stefano Franchini1, Luca Ferrante1, Lorenzo Ball3, Paolo Pelosi3, Giovanni Landoni2, Alberto Zangrillo2, Antonio Secchi4.   

Abstract

BACKGROUND: Acute respiratory failure (ARF) is a common cause of presentation to the Emergency Department (ED). High flow nasal cannula (HFNC) has been introduced as an alternative way to administer oxygen.
OBJECTIVES: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing HFNC with conventional oxygen therapy (COT) and noninvasive ventilation (NIV) exclusively in the ED setting.
METHODS: Inclusion criteria were: RCTs on adults with ARF admitted to the ED, investigating HFNC vs. COT or other modes of ventilation. Trials that compared HFNC support outside the ED, were published as an abstract, or nonrandomized were excluded.
RESULTS: Four RCTs comparing HFNC with COT and one HFNC to NIV met the criteria. Overall, 775 patients were included. The meta-analysis of the studies comparing HFNC and COT showed no differences in intubation requirement, treatment failure, hospitalization, or mortality. Intolerance was significantly higher with HFNC (risk ratio 6.81 95% confidence interval 1.18-39.19; p = 0.03). In the only available RCT comparing HFNC with NIV, no difference was found for intubation rate, treatment failure, tolerance, and dyspnea.
CONCLUSIONS: We did not find any benefit of HFNC compared with COT and NIV in terms of intubation requirement, treatment failure, hospitalization, and mortality; COT was better tolerated.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute respiratory failure; emergency department; high flow nasal cannula; noninvasive ventilation; oxygen therapy

Mesh:

Substances:

Year:  2019        PMID: 31421952     DOI: 10.1016/j.jemermed.2019.06.033

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  5 in total

Review 1.  Effectiveness and Harms of High-Flow Nasal Oxygen for Acute Respiratory Failure: An Evidence Report for a Clinical Guideline From the American College of Physicians.

Authors:  Arianne K Baldomero; Anne C Melzer; Nancy Greer; Brittany N Majeski; Roderick MacDonald; Eric J Linskens; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2021-04-27       Impact factor: 25.391

Review 2.  Use of nasal high flow oxygen during acute respiratory failure.

Authors:  Jean-Damien Ricard; Oriol Roca; Virginie Lemiale; Amanda Corley; Jens Braunlich; Peter Jones; Byung Ju Kang; François Lellouche; Stefano Nava; Nuttapol Rittayamai; Giulia Spoletini; Samir Jaber; Gonzalo Hernandez
Journal:  Intensive Care Med       Date:  2020-09-08       Impact factor: 17.440

3.  High flow oxygen therapy in the treatment of SARS-CoV-2 pneumonia.

Authors:  A González-Castro; E Cuenca Fito; A Fernandez-Rodriguez; P Escudero Acha; J C Rodríguez Borregán; Y Peñasco
Journal:  Med Intensiva (Engl Ed)       Date:  2021-01-18

4.  Comparison of outcomes of high-flow nasal cannula and noninvasive positive-pressure ventilation in patients with hypoxemia and various APACHE II scores after extubation.

Authors:  Xiaoke Shang; Yanggan Wang
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

5.  Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease.

Authors:  Takafumi Koyauchi; Hideki Yasui; Noriyuki Enomoto; Hirotsugu Hasegawa; Hironao Hozumi; Yuzo Suzuki; Masato Karayama; Kazuki Furuhashi; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Koshi Yokomura; Takafumi Suda
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.